COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Apr 10, 2023

JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus USA - English APAC - English

Mar 29, 2023

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients

Mar 8, 2023

JW Therapeutics Announces Initiation of Clinical Study of Carteyva in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma

Feb 28, 2023

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

Dec 12, 2022

JW Therapeutics Presents Latest Clinical Data on Carteyva in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

For More Press Releases

---